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Preamble
It is important that the medical profession play a significant
role in critically evaluating the use of diagnostic procedures
and therapies as they are introduced and tested in the
detection, management, or prevention of disease states. Rig-
orous and expert analysis of the available data documenting
the absolute and relative benefits and risks of those proce-
dures and therapies can produce helpful guidelines that
improve the effectiveness of care, optimize patient outcomes,
and favorably affect the overall cost of care by focusing
resources on the most effective strategies.
The American College of Cardiology (ACC) Foundation
and the American Heart Association (AHA) have jointly
engaged in the production of such guidelines in the area of
cardiovascular disease since 1980. The ACC/AHA Task
Force on Practice Guidelines, whose charge is to develop,
update, or revise practice guidelines for important cardiovas-
cular diseases and procedures, directs this effort. Writing
committees are charged with the task of performing an
assessment of the evidence and acting as an independent
group of authors to develop, update, or revise written recom-
mendations for clinical practice.
Experts in the subject under consideration have been selected
from both organizations to examine subject-specific data and
write guidelines. The process includes additional representatives
from other medical practitioner and specialty groups when
appropriate. Writing committees are specifically charged to
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perform a formal literature review, weigh the strength of
evidence for or against a particular treatment or procedure, and
include estimates of expected health outcomes where data exist.
Patient-specific modifiers, comorbidities, and issues of patient
preference that may influence the choice of particular tests or
therapies are considered, as well as frequency of follow-up and
cost-effectiveness. When available, information from studies on
cost will be considered; however, review of data on efficacy and
clinical outcomes will constitute the primary basis for preparing
recommendations in these guidelines.
The ACC/AHA Task Force on Practice Guidelines makes
every effort to avoid any actual, potential, or perceived conflicts
of interest that may arise as a result of an industry relationship or
personal interest of the writing committee. Specifically, all
members of the writing committee, as well as peer reviewers of
the document, were asked to provide disclosure statements of all
such relationships that may be perceived as real or potential
conflicts of interest. Writing committee members are also
strongly encouraged to declare a previous relationship with
industry that may be perceived as relevant to guideline devel-
opment. If a writing committee member develops a new rela-
tionship with industry during their tenure, they are required to
notify guideline staff in writing. The continued participation of
the writing committee member will be reviewed. These state-
ments are reviewed by the parent task force, reported orally to all
members of the writing committee at each meeting, and updated
and reviewed by the writing committee as changes occur. Please
refer to the methodology manual for ACC/AHA guideline
writing committees, available on the ACC and AHA World
Wide Web sites (http://www.acc.org/qualityandscience/clinical/
manual/manual_I.htm and http://circ.ahajournals.org/manual/),
for further description of the policy on relationships with
industry. Please see Appendix I for author relationships with
industry and Appendix II for peer reviewer relationships with
industry that are pertinent to these guidelines.
These practice guidelines are intended to assist healthcare
providers in clinical decision making by describing a range of
generally acceptable approaches for the diagnosis, manage-
ment, and prevention of specific diseases or conditions. These
guidelines attempt to define practices that meet the needs of
most patients in most circumstances. Clinical decision mak-
ing should consider the quality and availability of expertise in
the area where care is provided. These guideline recommen-
dations reflect a consensus of expert opinion after a thorough
review of the available, current scientific evidence and are
intended to improve patient care.
Patient adherence to prescribed and agreed on medical regi-
mens and lifestyles is an important aspect of treatment. Pre-
scribed courses of treatment in accordance with these recom-
mendations will only be effective if they are followed. Because
lack of patient understanding and adherence may adversely
affect treatment outcomes, physicians and other healthcare
providers should make every effort to engage the patient in active
participation with prescribed medical regimens and lifestyles.
If these guidelines are used as the basis for regulatory or payer
decisions, the ultimate goal is quality of care and serving the
patient’s best interests. The ultimate judgment regarding care of
a particular patient must be made by the healthcare provider and
the patient in light of all of the circumstances presented by that
patient. There are circumstances in which deviations from these
guidelines are appropriate.
The guidelines will be reviewed annually by the ACC/
AHA Task Force on Practice Guidelines and will be consid-
ered current unless they are updated, revised, or sunsetted and
withdrawn from distribution. The executive summary and
recommendations are published in the October 23, 2007,
issue of the Journal of the American College of Cardiology
and October 23, 2007, issue of Circulation. The full
text-guidelines are e-published in the same issue of the
journals noted above, as well as posted on the ACC
(www.acc.org) and AHA (www.americanheart.org) Web
sites. Copies of the full text and the executive summary are
available from both organizations.
Sidney C. Smith, Jr, MD, FACC, FAHA
Chair, ACC/AHA Task Force on Practice Guidelines
Alice K. Jacobs, MD, FACC, FAHA
Vice Chair, ACC/AHA Task Force on Practice Guidelines
I. Definition of the Problem
A. Purpose of These Guidelines
These guidelines represent an update to those published in
2002 and are intended for physicians and nonphysician
caregivers who are involved in the preoperative, operative,
and postoperative care of patients undergoing noncardiac
surgery. They provide a framework for considering cardiac
risk of noncardiac surgery in a variety of patient and surgical
situations. The writing committee that prepared these guide-
lines strove to incorporate what is currently known about
perioperative risk and how this knowledge can be used in the
individual patient.
The tables and algorithms provide quick references for deci-
sion making. The overriding theme of this document is that
intervention is rarely necessary to simply lower the risk of
surgery unless such intervention is indicated irrespective of the
preoperative context. The purpose of preoperative evaluation is
not to give medical clearance but rather to perform an evaluation
of the patient’s current medical status; make recommendations
concerning the evaluation, management, and risk of cardiac
problems over the entire perioperative period; and provide a
clinical risk profile that the patient, primary physician and
nonphysician caregivers, anesthesiologist, and surgeon can use
in making treatment decisions that may influence short- and
long-term cardiac outcomes. No test should be performed unless
it is likely to influence patient treatment. The goal of the
consultation is the optimal care of the patient.
B. Methodology and Evidence
The ACC/AHA Committee to Revise the 2002 Guidelines on
Perioperative Cardiovascular Evaluation for Noncardiac Sur-
gery conducted a comprehensive review of the literature
relevant to perioperative cardiac evaluation published since
the last publication of these guidelines in 2002. Literature
searches were conducted in the following databases: PubMed,
MEDLINE, and the Cochrane Library (including the Co-
chrane Database of Systematic Reviews and the Cochrane
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Controlled Trials Register). Searches were limited to the
English language, the years 2002 through 2007, and human
subjects. Related-article searches were conducted in MED-
LINE to find additional relevant articles. Finally, committee
members recommended applicable articles outside the scope
of the formal searches.
All of the recommendations in this guideline update were
converted from the tabular format used in the 2002 guidelines
to a listing of recommendations that has been written in full
sentences to express a complete thought, such that a recom-
mendation, even if separated and presented apart from the rest
of the document, would still convey the full intent of the
recommendation. It is hoped that this will increase the
reader’s comprehension of the guidelines. Also, the level of
evidence, either an A, B, or C, for each recommendation is
now provided (Table 1).
RECOMMENDATIONS
Recommendations for Preoperative Noninvasive
Evaluation of Left Ventricular Function
CLASS IIa
1. It is reasonable for patients with dyspnea of unknown origin to
undergo preoperative evaluation of left ventricular (LV) function.
(Level of Evidence: C)
2. It is reasonable for patients with current or prior heart failure with
worsening dyspnea or other change in clinical status to undergo
preoperative evaluation of LV function if not performed within 12
months. (Level of Evidence: C)
CLASS IIb
1. Reassessment of LV function in clinically stable patients with
previously documented cardiomyopathy is not well established.
(Level of Evidence: C)
CLASS III
1. Routine perioperative evaluation of LV function in patients is
not recommended. (Level of Evidence: B)
Recommendations for Preoperative Resting 12-Lead ECG
CLASS I
1. Preoperative resting 12-lead ECG is recommended for patients
with at least 1 clinical risk factor* who are undergoing vascular
surgical procedures. (Level of Evidence: B)
2. Preoperative resting 12-lead ECG is recommended for patients
with known coronary heart disease, peripheral arterial disease, or
cerebrovascular disease who are undergoing intermediate-risk
surgical procedures. (Level of Evidence: C)
CLASS IIa
1. Preoperative resting 12-lead ECG is reasonable in persons with no
clinical risk factorswho are under-going vascular surgical procedures.
(Level of Evidence: B)
CLASS IIb
1. Preoperative resting 12-lead ECG may be reasonable in patients
with at least 1 clinical risk factor who are undergoing
intermediate-risk operative procedures. (Level of Evidence: B)
CLASS III
1. Preoperative and postoperative resting 12-lead ECGs are not
indicated in asymptomatic persons undergoing low-risk surgical
procedures. (Level of Evidence: B)
Recommendations for Noninvasive Stress Testing Before
Noncardiac Surgery
CLASS I
1. Patients with active cardiac conditions (Table 2) in whom noncardiac
surgery is planned should be evaluated and treated per ACC/AHA
guidelines† before noncardiac surgery. (Level of Evidence: B)
CLASS IIa
1. Noninvasive stress testing of patients with 3 or more clinical risk
factors and poor functional capacity (less than 4 metabolic equiv-
alents [METs]) who require vascular surgery‡ is reasonable if it will
change management. (Level of Evidence: B)
CLASS IIb
1. Noninvasive stress testing may be considered for patients with at
least 1 to 2 clinical risk factors and poor functional capacity (less
than 4 METs) who require intermediate-risk noncardiac surgery if
it will change management. (Level of Evidence: B)
2. Noninvasive stress testing may be considered for patients with at
least 1 to 2 clinical risk factors and good functional capacity
(greater than or equal to 4 METs) who are undergoing vascular
surgery. (Level of Evidence: B)
CLASS III
1. Noninvasive testing is not useful for patients with no clinical risk
factors undergoing intermediate-risk noncardiac surgery. (Level of
Evidence: C)
2. Noninvasive testing is not useful for patients undergoing low-risk
noncardiac surgery. (Level of Evidence: C)
Recommendations for Preoperative Coronary
Revascularization With Coronary Artery Bypass
Grafting or Percutaneous Coronary Intervention
(All of the Class I indications below are consistent with the
ACC/AHA 2004 Guideline Update for Coronary Artery
Bypass Graft Surgery.)
*Clinical risk factors include history of ischemic heart disease, history
of compensated or prior heart failure, history of cerebrovascular disease,
diabetes mellitus, and renal insufficiency.
†ACC/AHA/ESC 2006 Guidelines for the Management of Patients With
Atrial Fibrillation (1), ACC/AHA 2005 Guideline Update for the Diagnosis
and Management of Chronic Heart Failure in the Adult (2), ACC/AHA
Guidelines for the Management of Patients With ST-Elevation Myocardial
Infarction (3), ACC/AHA/ESC Guidelines for the Management of Patients
With Supraventricular Arrhythmias (4), ACC/AHA Guidelines for the
Management of Patients With Unstable Angina and Non–ST-Segment
Elevation Myocardial Infarction (5), ACC/AHA 2006 Guidelines for the
Management of Patients With Valvular Heart Disease (6), and ACC/AHA/
ESC 2006 Guidelines for the Management of Patients With Ventricular
Arrhythmias and the Prevention of Sudden Cardiac Death (7).
‡Vascular surgery is defined by aortic and other major vascular
surgery and peripheral vascular surgery. See Table 4.
§High-risk unstable angina/non–ST-elevation MI patients were iden-
tified as those with age greater than 75 years, accelerating tempo of
ischemic symptoms in the preceding 48 hours, ongoing rest pain greater
than 20 minutes in duration, pulmonary edema, angina with S3 gallop or
rales, new or worsening mitral regurgitation murmur, hypotension,
bradycardia, tachycardia, dynamic ST-segment change greater than or
equal to 1 mm, new or presumed new bundle-branch block on ECG, or
elevated cardiac biomarkers, such as troponin.
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CLASS I
1. Coronary revascularization before noncardiac surgery is useful in
patients with stable angina who have significant left main coro-
nary artery stenosis. (Level of Evidence: A)
2. Coronary revascularization before noncardiac surgery is useful in
patients with stable angina who have 3-vessel disease. (Survival
benefit is greater when left ventricular ejection fraction is less than
0.50.) (Level of Evidence: A)
3. Coronary revascularization before noncardiac surgery is useful in
patients with stable angina who have 2-vessel disease with signif-
icant proximal left anterior descending stenosis and either ejec-
tion fraction less than 0.50 or demonstrable ischemia on nonin-
vasive testing. (Level of Evidence: A)
4. Coronary revascularization before noncardiac surgery is recom-
mended for patients with high-risk unstable angina or non–ST-
segment elevationmyocardial infarction (MI).§ (Level of Evidence: A)
5. Coronary revascularization before noncardiac surgery is recom-
mended in patients with acute ST-elevation MI. (Level of Evidence: A)
CLASS IIa
1. In patients in whom coronary revascularization with percutaneous
coronary intervention (PCI) is appropriate for mitigation of cardiac
symptoms and who need elective noncardiac surgery in the
subsequent 12 months, a strategy of balloon angioplasty or
bare-metal stent placement followed by 4 to 6 weeks of dual-
antiplatelet therapy is probably indicated. (Level of Evidence: B)
2. In patients who have received drug-eluting coronary stents and
who must undergo urgent surgical procedures that mandate the
discontinuation of thienopyridine therapy, it is reasonable to
continue aspirin if at all possible and restart the thienopyridine as
soon as possible. (Level of Evidence: C)
CLASS IIb
1. The usefulness of preoperative coronary revascularization is not
well established in high-risk ischemic patients (eg, abnormal
dobutamine stress echocardiogram with at least 5 segments of
wall-motion abnormalities). (Level of Evidence: C)
2. The usefulness of preoperative coronary revascularization is not
well established for low-risk ischemic patients with an abnormal
dobutamine stress echocardiogram (segments 1 to 4). (Level of
Evidence: B)
CLASS III
1. It is not recommended that routine prophylactic coronary revas-
cularization be performed in patients with stable coronary artery
disease (CAD) before noncardiac surgery. (Level of Evidence: B)
2. Elective noncardiac surgery is not recommended within 4 to 6 weeks
of bare-metal coronary stent implantation or within 12 months of
drug-eluting coronary stent implantation in patients in whom thien-
opyridine therapy or aspirin and thienopyridine therapy will need to
be discontinued perioperatively. (Level of Evidence: B)
3. Elective noncardiac surgery is not recommended within 4 weeks
of coronary revascularization with balloon angioplasty. (Level of
Evidence: B)
Recommendations for Beta-Blocker Medical Therapy
CLASS I
1. Beta blockers should be continued in patients undergoing surgery
who are receiving beta blockers to treat angina, symptomatic
arrhythmias, hypertension, or other ACC/AHA Class I guideline
indications. (Level of Evidence: C)
2. Beta blockers should be given to patients undergoing vascular
surgery who are at high cardiac risk owing to the finding of
ischemia on preoperative testing. (Level of Evidence: B)
CLASS IIa
1. Beta blockers are probably recommended for patients undergoing
vascular surgery in whom preoperative assessment identifies
coronary heart disease. (Level of Evidence: B)
2. Beta blockers are probably recommended for patients in whom
preoperative assessment for vascular surgery identifies high car-
diac risk, as defined by the presence of more than 1 clinical risk
factor.* (Level of Evidence: B)
3. Beta blockers are probably recommended for patients in whom
preoperative assessment identifies coronary heart disease or high
cardiac risk, as defined by the presence of more than 1 clinical risk
factor,* who are undergoing intermediate-risk or vascular surgery.
(Level of Evidence: B)
CLASS IIb
1. The usefulness of beta blockers is uncertain for patients who are
undergoing either intermediate-risk procedures or vascular sur-
gery, in whom preoperative assessment identifies a single clinical
risk factor.* (Level of Evidence: C)
2. The usefulness of beta blockers is uncertain in patients undergo-
ing vascular surgery with no clinical risk factors who are not
currently taking beta blockers. (Level of Evidence: B)
CLASS III
1. Beta blockers should not be given to patients undergoing surgery
who have absolute contraindications to beta blockade. (Level of
Evidence: C)
Recommendations for Statin Therapy
CLASS I
1. For patients currently taking statins and scheduled for noncardiac
surgery, statins should be continued. (Level of Evidence: B)
CLASS IIa
1. For patients undergoing vascular surgery with or without clinical
risk factors, statin use is reasonable. (Level of Evidence: B)
CLASS IIb
1. For patients with at least 1 clinical risk factor who are undergoing
intermediate-risk procedures, statins may be considered. (Level of
Evidence: C)
Recommendations for Alpha-2 Agonists
CLASS IIb
1. Alpha-2 agonists for perioperative control of hypertension may be
considered for patients with known CAD or at least 1 clinical risk
factor who are undergoing surgery. (Level of Evidence: B)
CLASS III
1. Alpha-2 agonists should not be given to patients undergoing
surgery who have contraindications to this medication. (Level of
Evidence: C)
Care should be taken in applying recommendations on beta-blocker
therapy to patients with decompensated heart failure, nonischemic
cardiomyopathy, or severe valvular heart disease in the absence of
coronary heart disease.
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Recommendation for Preoperative Intensive
Care Monitoring
CLASS IIb
1. Preoperative intensive care monitoring with a pulmonary artery
catheter for optimization of hemodynamic status might be con-
sidered; however, it is rarely required and should be restricted to a
very small number of highly selected patients whose presentation
is unstable and who have multiple comorbid conditions. (Level of
Evidence: B)
Recommendations for Use of Volatile Anesthetic Agents
CLASS IIa
1. It can be beneficial to use volatile anesthetic agents during
noncardiac surgery for the maintenance of general anesthesia in
hemodynamically stable patients at risk for myocardial ischemia.
(Level of Evidence: B)
Recommendation for Prophylactic Intraoperative
Nitroglycerin
CLASS IIb
1. The usefulness of intraoperative nitroglycerin as a prophylactic agent
to prevent myocardial ischemia and cardiac morbidity is unclear for
high-risk patients undergoing noncardiac surgery, particularly those
who have required nitrate therapy to control angina. The recommen-
dation for prophylactic use of nitroglycerinmust take into account the
anesthetic plan and patient hemodynamics andmust recognize that
vasodilation and hypovolemia can readily occur during anesthesia
and surgery. (Level of Evidence: C)
Recommendation for Use of
Transesophageal Echocardiography
CLASS IIa
1. The emergency use of intraoperative or perioperative transesoph-
ageal echocardiography is reasonable to determine the cause of
an acute, persistent, and life-threatening hemodynamic abnor-
mality. (Level of Evidence: C)
Recommendation for Maintenance of Body Temperature
CLASS I
1. Maintenance of body temperature in a normothermic range is
recommended for most procedures other than during periods in
which mild hypothermia is intended to provide organ protection
(eg, during high aortic cross-clamping). (Level of Evidence: B)
Recommendations for Perioperative Control of Blood
Glucose Concentration
CLASS IIa
1. It is reasonable that blood glucose concentration be controlled¶
during the perioperative period in patients with diabetes mellitus
or acute hyperglycemia who are at high risk for myocardial ische-
mia or who are undergoing vascular and major noncardiac surgical
procedures with planned intensive care unit admission. (Level of
Evidence: B)
CLASS IIb
1. The usefulness of strict control of blood glucose concentration¶
during the perioperative period is uncertain in patients with dia-
betes mellitus or acute hyperglycemia who are undergoing non-
cardiac surgical procedures without planned intensive care unit
admission. (Level of Evidence: C)
Recommendations for Perioperative Use of Pulmonary
Artery Catheters
CLASS IIb
1. Use of a pulmonary artery catheter may be reasonable in patients
at risk for major hemodynamic disturbances that are easily de-
tected by a pulmonary artery catheter; however, the decision must
be based on 3 parameters: patient disease, surgical procedure (ie,
intraoperative and postoperative fluid shifts), and practice setting
(experience in pulmonary artery catheter use and interpretation of
results), because incorrect interpretation of the data from a
pulmonary artery catheter may cause harm. (Level of Evidence: B)
CLASS III
1. Routine use of a pulmonary artery catheter perioperatively, espe-
cially in patients at low risk of developing hemodynamic distur-
bances, is not recommended. (Level of Evidence: A)
Recommendations for Intraoperative and Postoperative
Use of ST-Segment Monitoring
CLASS IIa
1. Intraoperative and postoperative ST-segment monitoring can be
useful to monitor patients with known CAD or those undergoing
vascular surgery, with computerized ST-segment analysis, when
available, used to detect myocardial ischemia during the periop-
erative period. (Level of Evidence: B)
CLASS IIb
1. Intraoperative and postoperative ST-segment monitoring may be
considered in patients with single or multiple risk factors for CAD
who are undergoing noncardiac surgery. (Level of Evidence: B)
Recommendations for Surveillance for Perioperative MI
CLASS I
1. Postoperative troponinmeasurement is recommended in patients
with ECG changes or chest pain typical of acute coronary syn-
drome. (Level of Evidence: C)
CLASS IIb
1. The use of postoperative troponin measurement is not well estab-
lished in patients who are clinically stable and have undergone
vascular and intermediate-risk surgery. (Level of Evidence: C)
CLASS III
1. Postoperative troponin measurement is not recommended in
asymptomatic stable patients who have undergone low-risk sur-
gery. (Level of Evidence: C)
II. General Approach to the Patient
This guideline focuses on the evaluation of the patient
undergoing noncardiac surgery who is at risk for periopera-
tive cardiac morbidity or mortality. In patients with known
CAD or the new onset of signs or symptoms suggestive of
CAD, baseline cardiac assessment should be performed. In
the asymptomatic patient, a more extensive assessment of
history and physical examination is warranted in those
individuals 50 years of age or older, because the evidence
related to the determination of cardiac risk factors and
derivation of a revised cardiac risk index occurred in this
population (8). Preoperative cardiac evaluation must there-¶Blood glucose levels less than 150 mg/dL appear to be beneficial.
1713JACC Vol. 50, No. 17, 2007 Fleisher et al.
October 23, 2007:1707–32 ACC/AHA 2007 Perioperative Guidelines
fore be carefully tailored to the circumstances that have
prompted the evaluation and to the nature of the surgical
illness. In patients in whom coronary revascularization is not
an option, it is often not necessary to perform a noninvasive
stress test. Under other, less urgent circumstances, the preop-
erative cardiac evaluation may lead to a variety of responses,
including cancellation of an elective procedure.
If a consultation is requested, then it is important to
identify the key questions and ensure that all of the periop-
erative caregivers are considered when providing a response.
Once a consultation has been obtained, the consultant should
review available patient data, obtain a history, and perform a
physical examination that includes a comprehensive cardio-
vascular examination and elements pertinent to the patient’s
problem and the proposed surgery. A critical role of the
consultant is to determine the stability of the patient’s
cardiovascular status and whether the patient is in optimal
medical condition within the context of the surgical illness.
The consultant may recommend changes in medication,
suggest preoperative tests or procedures, or propose higher
levels of care postoperatively. In general, preoperative tests
are recommended only if the information obtained will result
in a change in the surgical procedure performed, a change in
medical therapy or monitoring during or after surgery, or a
postponement of surgery until the cardiac condition can be
corrected or stabilized.
The consultant must also bear in mind that the periopera-
tive evaluation may be the ideal opportunity to effect the
long-term treatment of a patient with significant cardiac
disease or risk of such disease. The referring physician and
patient should be informed of the results of the evaluation and
implications for the patient’s prognosis. It is the cardiovas-
cular consultant’s responsibility to ensure clarity of commu-
nication so that findings and impressions will be incorporated
effectively into the patient’s overall plan of care. This ideally
would include direct communication with the surgeon, anes-
thesiologist, and other physicians, as well as frank discussion
directly with the patient and, if appropriate, the family. The
consultant should not use phrases such as “clear for surgery.”
A. History
A careful history is crucial to the discovery of cardiac and/or
comorbid diseases that would place the patient in a high
surgical risk category. The history should seek to identify
serious cardiac conditions such as unstable coronary syn-
dromes, prior angina, recent or past MI, decompensated heart
failure, significant arrhythmias, and severe valvular disease
(Table 2). It should also determine whether the patient has a
prior history of a pacemaker or implantable cardioverter
defibrillator (ICD) or a history of orthostatic intolerance and
should identify risk factors associated with increased periop-
erative cardiovascular risk. In patients with established car-
diac disease, any recent change in symptoms must be ascer-
tained. Accurate recording of current medications used,
including herbal and other nutritional supplements, and dos-
ages is essential. Use of alcohol, tobacco, and over-the-
counter and illicit drugs should be documented.
The history should also seek to determine the patient’s
functional capacity (Table 3). An assessment of an individu-
al’s capacity to perform a spectrum of common daily tasks
Table 2. Active Cardiac Conditions for Which the Patient Should Undergo
Evaluation and Treatment Before Noncardiac Surgery (Class I, Level of
Evidence: B)
Condition Examples
Unstable coronary syndromes Unstable or severe angina* (CCS class III or IV)†
Recent MI‡
Decompensated HF (NYHA functional class IV;
worsening or new-onset HF)
Significant arrhythmias High-grade atrioventricular block
Mobitz II atrioventricular block
Third-degree atrioventricular heart block
Symptomatic ventricular arrhythmias
Supraventricular arrhythmias (including atrial
fibrillation) with uncontrolled ventricular rate
(HR greater than 100 beats per minute at rest)
Symptomatic bradycardia
Newly recognized ventricular tachycardia
Severe valvular disease Severe aortic stenosis (mean pressure gradient
greater than 40 mm Hg, aortic valve area less
than 1.0 cm2, or symptomatic)
Symptomatic mitral stenosis (progressive
dyspnea on exertion, exertional presyncope, or HF)
*According to Campeau (9).
†May include stable angina in patients who are unusually sedentary.
‡The American College of Cardiology National Database Library defines recent MI as more than 7
days but less than or equal to 1 month (within 30 days).
CCS indicates Canadian Cardiovascular Society; HF, heart failure; HR, heart rate; MI, myocardial
infarction; NYHA, New York Heart Association.
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has been shown to correlate well with maximum oxygen
uptake by treadmill testing (10). A patient classified as high
risk owing to age or known CAD but who is asymptomatic
and runs for 30 minutes daily may need no further evaluation.
In contrast, a sedentary patient without a history of cardio-
vascular disease but with clinical factors that suggest in-
creased perioperative risk may benefit from a more extensive
preoperative evaluation (12–15).
B. Physical Examination and Routine
Laboratory Tests
A careful cardiovascular examination should include an
assessment of vital signs (including measurement of blood
pressure in both arms), carotid pulse contour and bruits,
jugular venous pressure and pulsations, auscultation of the
lungs, precordial palpation and auscultation, abdominal pal-
pation, and examination of the extremities for edema and
vascular integrity.
Anemia imposes a stress on the cardiovascular system that
may exacerbate myocardial ischemia and aggravate heart
failure (16). Hematocrits of less than 28% are associated with
an increased incidence of perioperative ischemia and postop-
erative complications in patients undergoing prostate and
vascular surgery (16 –18).
C. Multivariable Indices to Predict
Preoperative Cardiac Morbidity
The basic clinical evaluation obtained by history, physical
examination, and review of the ECG usually provides the
consultant with sufficient data to estimate cardiac risk. Lee et al.
(8) derived and validated a “simple index” for the prediction of
cardiac risk for stable patients undergoing nonurgent major
noncardiac surgery. Six independent risk correlates were iden-
tified: ischemic heart disease (defined as history of MI, history of
positive treadmill test, use of nitroglycerin, current complaints of
chest pain thought to be secondary to coronary ischemia, or ECG
with abnormal Q waves); congestive heart failure (defined as
history of heart failure, pulmonary edema, paroxysmal nocturnal
dyspnea, peripheral edema, bilateral rales, S3, or chest radio-
graph with pulmonary vascular redistribution); cerebral vascular
disease (history of transient ischemic attack or stroke); high-risk
surgery (abdominal aortic aneurysm or other vascular, thoracic,
abdominal, or orthopedic surgery); preoperative insulin treat-
ment for diabetes mellitus; and preoperative creatinine greater
than 2 mg per dL. Increasing numbers of risk factors correlated
with increased risk, yet the risk was substantially lower than
described in many of the original indices (8). The Revised
Cardiac Risk Index has become one of the most widely used risk
indices (8).
D. Clinical Assessment
In the original guidelines, the committee chose to segregate
clinical risk factors into major, intermediate, and minor risk
factors. There continues to be a group of active cardiac condi-
tions that when present indicate major clinical risk. The presence
of 1 or more of these conditions mandates intensive management
and may result in delay or cancellation of surgery unless the
surgery is emergent (Table 2). These include
● unstable coronary syndromes,
 unstable or severe angina,
 recent MI,
● decompensated heart failure,
● significant arrhythmias, and
● severe valvular disease.
Given the increasing use of the Revised Cardiac Risk Index,
the committee chose to replace the intermediate-risk category
with the clinical risk factors from the index, with the exclusion
of the type of surgery, which is incorporated elsewhere in the
approach to the patient. Clinical risk factors include
● history of heart disease,
● history of compensated or prior heart failure,
● history of cerebrovascular disease,
● diabetes mellitus, and
● renal insufficiency (8).
Table 3. Estimated Energy Requirements for Various Activities
1 MET
Can you  
Take care of yourself? 4 METs
Can you  
Climb a flight of stairs or walk up a hill?
4
™™
™™
™™
™™
™™
™™
™
Eat, dress, or use the toilet?
4
™™
™™
™™
™™
™™
™™
™™
™™
™™
™™
™™
™™
™™
™™ Walk on level ground at 4 mph (6.4 kph)?
Walk indoors around the house? Run a short distance?
Walk a block or 2 on level ground at 2 to
3 mph (3.2 to 4.8 kph)?
Do heavy work around the house like
scrubbing floors or lifting or moving heavy
furniture?
4 METs Do light work around the house like
dusting or washing dishes?
Participate in moderate recreational activities
like golf, bowling, dancing, doubles tennis, or
throwing a baseball or football?
Greater than 10 METs Participate in strenuous sports like swimming,
singles tennis, football, basketball, or skiing?
kph indicates kilometers per hour; MET, metabolic equivalent; and mph, miles per hour.
*Modified from Hlatky et al. (10), copyright 1989, with permission from Elsevier, and adapted from Fletcher et al. (11).
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A history of MI or abnormal Q waves by ECG is listed as
a clinical risk factor, whereas an acute MI (defined as at least
1 documented MI 7 days or less before the examination) or
recent MI (more than 7 days but less than or equal to 1 month
before the examination) with evidence of important ischemic
risk by clinical symptoms or noninvasive study is an active
cardiac condition. This definition reflects the consensus of the
ACC Cardiovascular Database Committee. Minor predictors
are recognized markers for cardiovascular disease that have
not been proven to independently increase perioperative risk,
for example, advanced age (greater than 70 years), abnormal
ECG (LV hypertrophy, left bundle-branch block, ST-T ab-
normalities), rhythm other than sinus, and uncontrolled sys-
temic hypertension. The presence of multiple minor predic-
tors might lead to a higher suspicion of CAD but is not
incorporated into the recommendations for treatment.
1. Stepwise Approach to Perioperative
Cardiac Assessment
Figure 1 presents in algorithmic form a framework for
determining which patients are candidates for cardiac testing.
Since publication of the perioperative cardiovascular evalua-
tion guidelines in 2002 (19), several new randomized trials
and cohort studies have led to modification of the original
algorithm. Given the availability of this evidence, the Writing
Committee chose to include the level of the recommendations
and strength of evidence for many of the pathways.
Step 1: The consultant should determine the urgency of
noncardiac surgery. In many instances, patient- or surgery-
specific factors dictate an obvious strategy (eg, emergent
surgery) that may not allow for further cardiac assessment or
treatment. In such cases, the consultant may function best by
providing recommendations for perioperative medical man-
agement and surveillance.
Step 2: Does the patient have 1 of the active cardiac
conditions or clinical risk factors listed in Table 2? If not,
proceed to Step 3. In patients being considered for elective
noncardiac surgery, the presence of unstable coronary dis-
ease, decompensated heart failure, or severe arrhythmia or
valvular heart disease usually leads to cancellation or delay of
surgery until the cardiac problem has been clarified and
treated appropriately. Examples of unstable coronary syn-
dromes include previous MI with evidence of important
ischemic risk by clinical symptoms or noninvasive study,
unstable or severe angina, and new or poorly controlled
ischemia-mediated heart failure. Many patients in these
Figure 1. Cardiac evaluation and care algorithm for noncardiac surgery based on active clinical conditions, known cardiovascular dis-
ease, or cardiac risk factors for patients 50 years of age or greater. *See Table 2 for active clinical conditions. †See Table 3 for esti-
mated MET level equivalent. ‡Clinical risk factors include ischemic heart disease, compensated or prior heart failure, diabetes mellitus,
renal insufficiency, and cerebrovascular disease. §Consider perioperative beta blockade (see Table 5) for populations in which this has
been shown to reduce cardiac morbidity/mortality. ACC/AHA indicates American College of Cardiology/American Heart Association;
HR, heart rate; LOE, level of evidence; and MET, metabolic equivalent.
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circumstances are referred for coronary angiography to assess
further therapeutic options. Depending on the results of the
test or interventions and the risk of delaying surgery, it may
be appropriate to proceed to the planned surgery with
maximal medical therapy.
Step 3: Is the patient undergoing low-risk surgery? In these
patients, interventions based on cardiovascular testing in
stable patients would rarely result in a change in manage-
ment, and it would be appropriate to proceed with the planned
surgical procedure.
Step 4: Does the patient have good functional capacity
without symptoms? In highly functional asymptomatic pa-
tients, management will rarely be changed on the basis of
results of any further cardiovascular testing. It is therefore
appropriate to proceed with the planned surgery. In patients
with known cardiovascular disease or at least 1 clinical risk
factor, perioperative heart rate control with beta blockade
appears appropriate as outlined in Section VI.B.
If the patient has not had a recent exercise test, functional
status can usually be estimated from the ability to perform
activities of daily living (20). For this purpose, functional
capacity has been classified as excellent (greater than 10
METs), good (7 to 10 METs), moderate (4 to 7 METs), poor
(less than 4 METs), or unknown. The Duke Activity Status
Index (Table 3) contains questions that can be used to
estimate the patient’s functional capacity (21).
Step 5: If the patient has poor functional capacity, is
symptomatic, or has unknown functional capacity, then the
presence of active clinical risk factors will determine the need
for further evaluation. If the patient has no clinical risk
factors, then it is appropriate to proceed with the planned
surgery, and no further change in management is indicated.()
If the patient has 1 or 2 clinical risk factors, then it is
reasonable either to proceed with the planned surgery or, if
appropriate, with heart rate control with beta blockade, or to
consider testing if it will change management. In patients
with 3 or more clinical risk factors, the surgery-specific
cardiac risk is important.
The surgery-specific cardiac risk (Table 4) of noncardiac
surgery is related to 2 important factors. First, the type of
surgery itself may identify a patient with a greater likelihood
of underlying heart disease and higher perioperative morbid-
ity and mortality. Perhaps the most extensively studied
example is vascular surgery, in which underlying CAD is
present in a substantial portion of patients. If the patient is
undergoing vascular surgery, recent studies suggest that
testing should only be considered if it will change manage-
ment. Other types of surgery may be associated with similar
risk to vascular surgery but have not been studied extensively.
In nonvascular surgery in which the perioperative morbidity
related to the procedures ranges from 1% to 5%
(intermediate-risk surgery), there are insufficient data to
determine the best strategy (proceeding with the planned
surgery with tight heart rate control with beta blockade or
further cardiovascular testing if it will change management).
III. Disease-Specific Approaches
A. Coronary Artery Disease
1. Patients With Known CAD
In patients with known CAD, as well as those with previously
occult coronary disease, the questions become 1) What is the
amount of myocardium in jeopardy? 2) What is the ischemic
threshold, that is, the amount of stress required to produce
ischemia? 3) What is the patient’s ventricular function? and
4) Is the patient on his or her optimal medical regimen?
Clarification of these questions is an important goal of the
preoperative history and physical examination, and selected
noninvasive testing is used to determine the patient’s prog-
nostic gradient of ischemic response during stress testing.
B. Hypertension
For stage 3 hypertension (systolic blood pressure greater than
or equal to 180 mm Hg and diastolic blood pressure greater
than or equal to 110 mm Hg), the potential benefits of
delaying surgery to optimize the effects of antihypertensive
medications should be weighed against the risk of delaying
the surgical procedure. With rapidly acting intravenous
agents, blood pressure can usually be controlled within a
matter of several hours. One randomized trial was unable to
demonstrate a benefit to delaying surgery in chronically
treated hypertensive patients who presented for noncardiac
surgery with diastolic blood pressure between 110 and
130 mm Hg and who had no previous MI, unstable or severe
angina pectoris, renal failure, pregnancy-induced hyperten-
sion, LV hypertrophy, previous coronary revascularization,
aortic stenosis, preoperative dysrhythmias, conduction de-
fects, or stroke (23).
Several authors have suggested withholding angiotensin-
converting enzyme inhibitors and angiotensin receptor antag-
onists the morning of surgery (24 –26). Consideration should
be given to restarting angiotensin-converting enzyme inhibi-
tors in the postoperative period only after the patient is
euvolemic, to decrease the risk of perioperative renal
dysfunction.
C. Valvular Heart Disease
In symptomatic aortic stenosis, elective noncardiac surgery
should generally be postponed or canceled. Such patients
Table 4. Cardiac Risk* Stratification for Noncardiac
Surgical Procedures
Risk Stratification Procedure Examples
Vascular (reported cardiac risk
often more than 5%)
Aortic and other major vascular surgery
Peripheral vascular surgery
Intermediate (reported cardiac
risk generally 1% to 5%)
Intraperitoneal and intrathoracic surgery
Carotid endarterectomy
Head and neck surgery
Orthopedic surgery
Prostate surgery
Low† (reported cardiac risk
generally less than 1%)
Endoscopic procedures
Superficial procedure
Cataract surgery
Breast surgery
Ambulatory surgery
*Combined incidence of cardiac death and nonfatal myocardial infarction.
†These procedures do not generally require further preoperative cardiac testing.
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require aortic valve replacement before elective but necessary
noncardiac surgery. If the aortic stenosis is severe but
asymptomatic, the surgery should be postponed or canceled if
the valve has not been evaluated within the year. On the other
hand, in patients with severe aortic stenosis who refuse
cardiac surgery or are otherwise not candidates for aortic
valve replacement, noncardiac surgery can be performed with
a mortality risk of approximately 10% (27,28). If a patient is
not a candidate for valve replacement, percutaneous balloon
aortic valvuloplasty may be reasonable as a bridge to surgery
in hemodynamically unstable adult patients with aortic ste-
nosis who are at high risk for aortic valve replacement
surgery and may be reasonable in adult patients with aortic
stenosis in whom aortic valve replacement cannot be per-
formed because of serious comorbid conditions (6,29).
Significant mitral stenosis increases the risk of heart
failure. However, preoperative surgical correction of mitral
valve disease is not indicated before noncardiac surgery,
unless the valvular condition should be corrected to prolong
survival and prevent complications unrelated to the proposed
noncardiac surgery. When the stenosis is severe, the patient
may benefit from balloon mitral valvuloplasty or open surgi-
cal repair before high-risk surgery (30).
In patients with persistent or permanent atrial fibrillation
who are at high risk for thromboembolism, preoperative and
postoperative therapy with intravenous heparin or subcutane-
ous low-molecular-weight heparin may be considered to
cover periods of subtherapeutic anticoagulation (1,31–33).
Patients with a mechanical prosthetic valve are of concern
because of the need for endocarditis prophylaxis (34) when
they undergo surgery that may result in bacteremia and the
need for careful anticoagulation management. The Seventh
American College of Chest Physicians Consensus Confer-
ence on Antithrombotic and Thrombolytic Therapy (35)
recommends the following: for patients who require mini-
mally invasive procedures (dental work, superficial biopsies),
the recommendation is to briefly reduce the international
normalized ratio to the low or subtherapeutic range and
resume the normal dose of oral anticoagulation immediately
after the procedure. Perioperative heparin therapy is recom-
mended for patients in whom the risk of bleeding with oral
anticoagulation is high and the risk of thromboembolism
without anticoagulation is also high (mechanical valve in the
mitral position; Bjork-Shiley valve; recent [ie, less than 1
year] thrombosis or embolus; or 3 or more of the following
risk factors: atrial fibrillation, previous embolus at any time,
hypercoagulable condition, mechanical prosthesis, and LV
ejection fraction less than 30%) (36). For patients between
these 2 extremes, physicians must assess the risk and benefit
of reduced anticoagulation versus perioperative heparin
therapy.
IV. Surgery-Specific Issues
Although different operations are associated with different
cardiac risks, these differences are most often a reflection of
the context in which the patient undergoes surgery (stability
or opportunity for adequate preoperative preparation),
surgery-specific factors (eg, fluid shifts, stress levels, dura-
tion of procedure, or blood loss), or patient-specific factors
(the incidence of CAD associated with the condition for
which the patient is undergoing surgery). The surgical pro-
cedures have been classified as low risk, high risk, and
vascular. Although coronary disease is the overwhelming risk
factor for perioperative morbidity, procedures with different
levels of stress are associated with different levels of mor-
bidity and mortality. Superficial and ophthalmologic proce-
dures represent the lowest risk and are rarely associated with
excess morbidity and mortality. Major vascular procedures
represent the highest-risk procedures and are now considered
distinctly in the decision to perform further evaluation be-
cause of the large body of evidence regarding the value of
perioperative interventions in this population (Figure 1). Both
endovascular aortic aneurysm repair and carotid endarterec-
tomy should be considered within the intermediate-risk cat-
egory, distinct from the open vascular surgery procedures, on
the basis of their preoperative morbidity and mortality rates,
but clinicians should incorporate the similarly poor long-term
survival rates that accompany these procedures into their
decision-making processes. Within the intermediate-risk cat-
egory, morbidity and mortality vary depending on the surgi-
cal location and extent of the procedure. Some procedures
may be short, with minimal fluid shifts, whereas others may
be associated with prolonged duration, large fluid shifts, and
greater potential for postoperative myocardial ischemia and
respiratory depression. Therefore, the physician must exer-
cise judgment to correctly assess perioperative surgical risks
and the need for further evaluation.
V. Supplemental Preoperative
Evaluation
A. Assessment of LV Function
Resting LV function has been evaluated preoperatively be-
fore noncardiac surgery by radionuclide angiography, echo-
cardiography, and contrast ventriculography. It is noteworthy
that resting LV function was not found to be a consistent
predictor of perioperative ischemic events.
B. Assessment of Risk for CAD and
Assessment of Functional Capacity
1. The 12-Lead ECG
Although the optimal time interval between obtaining a
12-lead ECG and elective surgery is unknown, general
consensus suggests that an ECG within 30 days of surgery is
adequate for those with stable disease in whom a preoperative
ECG is indicated.
2. Exercise Stress Testing for Myocardial Ischemia and
Functional Capacity
The aim of supplemental preoperative testing is to provide an
objective measure of functional capacity, to identify the
presence of important preoperative myocardial ischemia or
cardiac arrhythmias, and to estimate perioperative cardiac
risk and long-term prognosis.
3. Noninvasive Stress Testing
Pharmacological stress with vasodilators or adrenergic stim-
ulation in conjunction with radionuclide or echocardiographic
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cardiac imaging has been shown to predict perioperative
cardiac events in patients scheduled for noncardiac surgery
who are unable to exercise (37). Importantly, perioperative
cardiac risk is directly related to the extent of jeopardized
viable myocardium identified by stress cardiac imaging (37).
The expertise of the practitioner’s available stress labora-
tory resources in identifying severe coronary disease is as
important as the particular type of stress test ordered. For
patients with unstable myocardial ischemia, who are at high
risk for noncardiac surgery, it is usually appropriate to
proceed with coronary angiography or to attempt to stabilize
them with aggressive medical treatment rather than to per-
form a stress test.
VI. Perioperative Therapy
A. Preoperative Coronary Revascularization
With Coronary Artery Bypass Grafting or PCI
1. Preoperative Coronary Artery Bypass Grafting
Until recently, all of the evidence regarding the value of
surgical coronary revascularization was derived from cohort
studies in patients who presented for noncardiac surgery after
successful cardiac surgery. There are now several randomized
trials that have assessed the overall benefit of prophylactic
coronary bypass surgery to lower the perioperative cardiac
risk of noncardiac surgery, the results of which can be applied
to specific subsets of patients and will be discussed later.
The first large, randomized trial (Coronary Artery Revascu-
larization Prophylaxis [CARP]) was published by McFalls and
colleagues (38), who randomly assigned 510 patients with
significant coronary artery stenosis from among 5859 patients
scheduled for vascular operations to either coronary artery
revascularization before surgery or no revascularization before
surgery. The authors concluded that routine coronary revascu-
larization in patients with stable cardiac symptoms before
elective vascular surgery does not significantly alter the long-
term outcome or short-term risk of death or MI.
The DECREASE (Dutch Echocardiographic Cardiac Risk
Evaluation Applying Stress Echocardiography) II trial (39)
was designed to evaluate the utility of cardiac testing in
patients undergoing major vascular surgery with intermediate
cardiac risk factors and adequate beta-blocker therapy. A
composite end point of death and nonfatal MI was assessed at
30 days after vascular surgery. This study confirms that
extensive cardiac ischemia is a risk factor for perioperative
cardiac events, but it was too small to assess the effect of
revascularization.
The DECREASE-V pilot study (40) identified a high-risk
cohort of patients scheduled for vascular surgery who were
randomized to best medical therapy and revascularization or
best medical therapy alone before vascular surgery. There
was no difference in the combined outcomes of death or MI
at 30 days or 1 year between the revascularization and
medical therapy groups, although there was a high incidence
of cardiac events in this high-risk cohort. This study was not
sized to definitively answer the question as to the value of
preoperative revascularization in high-risk patients; however,
the findings are consistent with the previously published
literature suggesting a lack of benefit of preoperative coro-
nary revascularization in preventing death or MI. The indi-
cations for preoperative surgical coronary revascularization,
therefore, are essentially identical to those recommended by
the ACC/AHA 2004 Guideline Update for Coronary Artery
Bypass Graft Surgery and the accumulated data on which
those conclusions were based (41).
2. Preoperative PCI
Review of the literature suggests that PCI before noncardiac
surgery is of no value in preventing perioperative cardiac
events, except in those patients in whom PCI is independently
indicated for an acute coronary syndrome. However, un-
scheduled noncardiac surgery in a patient who has undergone
a prior PCI presents special challenges, particularly with
regard to management of dual-antiplatelet agents required in
those who receive coronary stents.
3. PCI Without Stents: Coronary Balloon Angioplasty
Several retrospective series of coronary balloon angioplasty
before noncardiac surgery have been reported (42– 49). On
the basis of the available literature, delaying noncardiac
surgery for more than 8 weeks after balloon angioplasty
increases the chance that restenosis at the angioplasty site will
have occurred and theoretically increases the chances of
perioperative ischemia or MI. However, performing the
surgical procedure too soon after the PCI procedure might
also be hazardous. Delaying surgery for at least 2 to 4 weeks
after balloon angioplasty to allow for healing of the vessel
injury at the balloon treatment site is supported by a study by
Brilakis et al. (49). Daily aspirin antiplatelet therapy should
be continued perioperatively. The risk of stopping the aspirin
should be weighed against the benefit of reduction in bleed-
ing complications from the planned surgery.
4. PCI: Bare-Metal Coronary Stents
If a coronary stent is used in the revascularization procedure,
as in the majority of percutaneous revascularization proce-
dures, further delay of noncardiac surgery may be beneficial.
Bare-metal stent thrombosis is most common in the first 2
weeks after stent placement and is exceedingly rare (less than
0.1% of most case series) more than 4 weeks after stent
placement (50,51). Given that stent thrombosis will result in
Q-wave MI or death in the majority of patients in whom it
occurs, and given that the risk of bare-metal stent thrombosis
diminishes after endothelialization of the stent has occurred
(which generally takes 4 to 6 weeks), it appears reasonable to
delay elective noncardiac surgery for 4 to 6 weeks to allow
for at least partial endothelialization of the stent, but not for
more than 12 weeks, when restenosis may begin to occur.
A thienopyridine (ticlopidine or clopidogrel) is generally
administered with aspirin for 4 weeks after bare-metal stent
placement. The thienopyridines and aspirin inhibit platelet
aggregation and reduce stent thrombosis but increase the risk
of bleeding. Rapid endothelialization of bare-metal stents
makes late thrombosis rare, and thienopyridines are rarely
needed for more than 4 weeks after implantation of bare-
metal stents. For this reason, delaying surgery 4 to 6 weeks
after bare-metal stent placement allows proper thienopyridine
use to reduce the risk of coronary stent thrombosis; then, after
the thienopyridine has been discontinued, the noncardiac
surgery can be performed. However, once the thienopyridine
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is stopped, its effects do not diminish immediately. It is for
this reason that some surgical teams request a 1-week delay
after thienopyridines are discontinued before the patient
proceeds to surgery. In patients with bare-metal stents, daily
aspirin antiplatelet therapy should be continued periopera-
tively. The risk of stopping the aspirin should be weighed
against the benefit of reduction in bleeding complications
from the planned surgery. In the setting of noncardiac surgery
in patients who have recently received a bare-metal stent, the
risk of stopping dual-antiplatelet agents prematurely (within 4
weeks of implantation) is significant compared with the risk
of major bleeding from most commonly performed surgeries.
5. PCI: Drug-Eluting Stents
Thrombosis of drug-eluting stents may occur late and has been
reported up to 1.5 years after implantation, particularly in the
context of discontinuation of antiplatelet agents before noncar-
diac surgery (52,53). In January 2007, an AHA/ACC/Society for
Cardiovascular Angiography and Interventions (SCAI)/Ameri-
can College of Surgeons (ACS)/American Diabetes Association
(ADA) science advisory was issued regarding the prevention of
premature discontinuation of dual-antiplatelet therapy in patients
with coronary artery stents (54). This advisory report (54)
concluded that premature discontinuation of dual-antiplatelet
therapy markedly increases the risk of catastrophic stent throm-
bosis and death and/or MI. To eliminate the premature discon-
tinuation of thienopyridine therapy, the advisory group recom-
mended the following:
● Elective procedures for which there is a significant risk of
perioperative or postoperative bleeding should be deferred
until patients have completed an appropriate course of
thienopyridine therapy (12 months after drug-eluting stent
implantation if they are not at high risk of bleeding and a
minimum of 1 month for bare-metal stent implantation).
● For patients treated with drug-eluting stents who are to
undergo subsequent procedures that mandate discontinua-
tion of thienopyridine therapy, aspirin should be continued
if at all possible and the thienopyridine restarted as soon as
possible after the procedure because of concerns about
late-stent thrombosis.
Given the above reports and recommendations, the use of
drug-eluting stents for coronary revascularization before immi-
nent or planned noncardiac surgery that will necessitate the
discontinuation of dual-antiplatelet agents is not recommended.
In patients with stable CAD, the indications for PCI in the
preoperative setting should be identical to those developed by
the joint ACC/AHA Task Force that provided guidelines for
the use of PCI in patients with stable angina and asymptom-
atic ischemia (55). There is no evidence to support prophy-
lactic preoperative percutaneous revascularization in patients
with asymptomatic ischemia or stable angina, particularly
with drug-eluting stents. Similarly, there is little evidence to
show how long a more distant PCI (ie, months to years before
noncardiac surgery) protects against perioperative MI or
death. Because additional coronary restenosis is unlikely to
occur more than 8 to 12 months after PCI (whether or not a
stent is used), it is reasonable to expect ongoing protection
against untoward perioperative ischemic complications in
currently asymptomatic, active patients who had been symp-
tomatic before complete percutaneous coronary revascular-
ization more than 8 to 12 months previously.
6. Perioperative Management of Patients With Prior
PCI Undergoing Noncardiac Surgery
For patients who have undergone successful coronary inter-
vention with or without stent placement before planned or
unplanned noncardiac surgery, there is uncertainty regarding
how much time should pass before the noncardiac procedure
is performed. One approach is outlined in Figure 2, which is
based on expert opinion. Given the reports of late drug-
eluting stent thrombosis and the current recommendations
discussed above, clinicians should remain vigilant even
beyond 365 days after drug-eluting stent placement. The
times of 14, 30 to 45, and 365 days for balloon angioplasty,
bare-metal stent, and drug-eluting stent, respectively, recom-
mended in Figure 2 are somewhat arbitrary because of a lack
of high-quality evidence.
Consideration should be given to continuing dual-
antiplatelet therapy in the perioperative period for any patient
needing noncardiac surgery that falls within the time frame
that requires dual-antiplatelet therapy, particularly those who
have received drug-eluting stents. In addition, consideration
should be given to continuing dual-antiplatelet therapy peri-
operatively beyond the recommended time frame in any
patient at high risk for the consequences of stent thrombosis,
Balloon 
angioplasty
Bare-metal 
stent
Drug-eluting 
stent
Delay for elective or 
nonurgent surgery
<14 days >14 days
Proceed to the 
operation room 
with aspirin
Delay for elective or 
nonurgent surgery
>30-45 days <30-45 days
Proceed to the 
operating room 
with aspirin
<365 days
>365 days
Previous PCI
Time since PCI
Figure 2. Proposed approach to the
management of patients with previous
percutaneous coronary intervention
(PCI) who require noncardiac surgery,
based on expert opinion.
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such as patients in whom previous stent thrombosis has
occurred, after left main stenting, after multivessel stenting,
and after stent placement in the only remaining coronary
artery or graft conduit. Even after thienopyridines have been
discontinued, serious consideration should be given to con-
tinuation of aspirin antiplatelet therapy perioperatively in any
patient with previous placement of a drug-eluting stent. The
risk of stopping antiplatelet therapy should be weighed
against the benefit of reduction in bleeding complications
from the planned surgery. If thienopyridines must be discon-
tinued before major surgery, aspirin should be continued and
the thienopyridine restarted as soon as possible. There is no
evidence that warfarin, antithrombotics, or glycoprotein IIb/
IIIa agents will reduce the risk of stent thrombosis after
discontinuation of oral antiplatelet agents (54).
7. Perioperative Management in Patients Who Have
Received Intracoronary Brachytherapy
Intracoronary radiation with gamma or beta brachytherapy
has been used in the past to treat recurrent in-stent restenosis.
Antiplatelet therapy should be continued as per the ACC/
AHA/SCAI 2005 Guideline Update for Percutaneous Coro-
nary Intervention, with a Class IIa recommendation (55).
Serious consideration should be given to continuing dual-
antiplatelet therapy in the perioperative period for any patient
who has received brachytherapy for restenosis or in-stent reste-
nosis, particularly those in whom additional stents (bare-metal or
drug-eluting) were placed at the time of or subsequent to the
administration of brachytherapy. The risk of stopping antiplate-
let therapy should be weighed against the benefit of reduction in
bleeding complications from the planned surgery.
8. Strategy of Percutaneous Revascularization in Patients
Needing Urgent Noncardiac Surgery
Patients who require percutaneous coronary revascularization
in whom near-term noncardiac surgery is necessary require
special consideration (54,56). A potential strategy is outlined
in Figure 3. Percutaneous coronary revascularization should
not be routinely performed in patients who need noncardiac
surgery unless clearly indicated for high-risk coronary anat-
omy, unstable angina, MI, or hemodynamically or rhythmi-
cally unstable active CAD amenable to percutaneous inter-
vention. If PCI is necessary, then the urgency of the
noncardiac surgery and the risk of bleeding associated with
the surgery in a patient taking dual-antiplatelet agents need to
be considered. If there is little risk of bleeding or if the
noncardiac surgery can be delayed 12 months or more, then
PCI with drug-eluting stents and prolonged aspirin and
thienopyridine therapy could be considered if the patient
meets the criteria outlined in the AHA/ACC/SCAI/ACS/
ADA Science Advisory Group recommendations discussed
above (54). If the noncardiac surgery is likely to occur within
1 to 12 months, then a strategy of bare-metal stenting and 4
to 6 weeks of aspirin and thienopyridine therapy with
continuation of aspirin perioperatively should be considered.
Although the risk of restenosis with this strategy is higher
than with drug-eluting stents, restenotic lesions are usually
not life-threatening, even though they may present as an acute
coronary syndrome (57), and they can usually be dealt with
by repeat PCI if necessary. If the noncardiac surgery is
imminent (within 2 to 6 weeks) and the risk of bleeding is
high, then consideration should be given to balloon angio-
plasty and provisional bare-metal stenting plus continued
Balloon 
angioplasty
Bare-metal 
stent
Drug-eluting 
stent
14 to 29 days 30 to 365 days Greater than 365 days
Acute MI, high-risk 
ACS,  or high-risk 
cardiac anatomy
Timing of Surgery
Bleeding risk of surgery Stent and continued dual-antiplatelet therapyLow
Not low
(COR IIb/LOE C) (COR IIa/LOE C) (COR IIb/LOE C)
(COR IIb/LOE C)
Figure 3. Treatment for patients requiring percutaneous coronary intervention who need subsequent surgery. ACS indicates acute cor-
onary syndrome; COR, class of recommendation; LOE, level of evidence; and MI, myocardial infarction.
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aspirin antiplatelet monotherapy, with restenosis dealt with
by repeat PCI if necessary. If the noncardiac surgery is urgent
or emergent, then cardiac risks, the risk of bleeding, and the
long-term benefit of coronary revascularization must be
weighed, and if coronary revascularization is absolutely
necessary, coronary artery bypass grafting combined with the
noncardiac surgery could be considered.
B. Perioperative Medical Therapy
1. Perioperative Beta-Blocker Therapy
Since publication of the ACC/AHA focused update on periop-
erative beta-blocker therapy, several randomized trials have been
published that have not demonstrated the efficacy of these
agents, in contrast to the earlier studies that demonstrated
efficacy (58,59). Although many of the randomized controlled
trials of beta blocker therapy are small, the weight of evidence—
especially in aggregate—suggests a benefit to perioperative beta
blockade during noncardiac surgery in high-risk patients (Table
5). Current studies suggest that beta blockers reduce periopera-
tive ischemia and may reduce the risk of MI and death in patients
with known CAD. Available evidence strongly suggests but
does not definitively prove that when possible, beta blockers
should be started days to weeks before elective surgery. Addi-
tionally, data suggest that long-acting beta blockade may be
superior to short-acting beta blockade (60).
a. Titration of Beta Blockers
Feringa and colleagues (61) performed an observational cohort
study of 272 vascular surgery patients. An absolute mean
perioperative heart rate of less than 70 beats per minute was
associated with the best outcome. Poldermans and colleagues
(39) randomly assigned 770 intermediate-risk patients to cardiac
stress testing (n386) or no testing (n384). The authors
concluded that cardiac testing can safely be omitted in
intermediate-risk patients, provided that beta blockers aimed at
tight heart rate control are prescribed. Accumulating evidence
suggests that effective heart rate control with beta blockers
should be targeted at less than 65 beats per minute.
b. Withdrawal of Beta Blockers
Concerns regarding the discontinuation of beta-blocker
therapy in the perioperative period have existed for several
decades (62– 64). As noted in the recommendations, continua-
tion of beta-blocker therapy in the perioperative period is a Class
I indication, and accumulating evidence suggests that titration to
maintain tight heart rate control should be the goal.
2. Perioperative Statin Therapy
The evidence accumulated thus far suggests a protective effect
of perioperative statin use on cardiac complications during
noncardiac surgery. Hindler and colleagues (65) conducted a
meta-analysis to evaluate the overall effect of preoperative statin
therapy, and a 44% reduction in mortality was observed. Le
Manach and colleagues (66) demonstrated that postoperative
statin withdrawal (more than 4 days) was an independent
predictor of postoperative myonecrosis. Most of these data are
observational and identify patients in whom time of initiation of
statin therapy and duration of statin therapy are unclear.
3. Alpha-2 Agonists
Wijeysundera and colleagues (67) performed a meta-analysis of
perioperative alpha-2 agonist administration through 2002 com-
prising 23 trials enrolling 3395 patients. Alpha-2 agonists
reduced mortality (relative risk 0.76, 95% CI 0.63 to 0.91) and
MI (relative risk 0.66, 95% CI 0.46 to 0.94) during vascular
surgery.
More recently, Wallace et al. (68) conducted a prospective,
double-blinded, clinical trial on patients with or at risk for
CAD and determined that administration of clonidine had
minimal hemodynamic effects and reduced postoperative
mortality for up to 2 years.
4. Perioperative Calcium Channel Blockers
A meta-analysis of perioperative calcium channel blockers in
noncardiac surgery that was published in 2003 identified 11
studies involving 1007 patients (69). Calcium channel block-
ers significantly reduced ischemia (relative risk 0.49, 95%
confidence interval 0.30 to 0.80, P0.004) and supraventric-
ular tachycardia (relative risk 0.52, 95% confidence interval
0.37 to 0.72, P less than 0.0001) and were associated with
trends toward reduced death and MI.
C. Intraoperative Electromagnetic
Interference With Implanted Pacemakers
and Cardioverter Defibrillators
It is important to be aware of the potential for adverse interac-
tions between electrical/magnetic activity and pacemaker or ICD
function that may occur during the operative period. A practice
advisory on this topic has been published recently by the
American Society of Anesthesiology (70). Patients with perma-
nent pacemakers who are pacemaker dependent should have
their device evaluated within 3 to 6 months before significant
surgical procedures, as well as after surgery. Significant surgical
Table 5. Recommendations for Perioperative Beta-Blocker Therapy Based on Published Randomized Clinical Trials
Surgery
No Clinical
Risk Factors
1 or More Clinical
Risk Factors
CHD or High
Cardiac Risk
Patients Currently
Taking Beta Blockers
Vascular Class IIb,
Level of Evidence: B
Class IIa,
Level of Evidence: B
Patients found to have myocardial ischemia on
preoperative testing: Class I, Level of Evidence: B*
Class I,
Level of Evidence: B
Patients without ischemia or no previous test:
Class IIa, Level of Evidence: B
Intermediate risk    Class IIb,
Level of Evidence: C
Class IIa, Level of Evidence: B Class I,
Level of Evidence: C
Low risk          Class I,
Level of Evidence: C
See Table 4 for definition of procedures. Ellipses (  ) indicate that data were insufficient to determine a class of recommendation or level of
evidence. See text for further discussion. CHD indicates coronary heart disease.
*Applies to patients found to have coronary ischemia on preoperative testing.
†Applies to patients found to have coronary heart disease.
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procedures include major abdominal or thoracic surgery, partic-
ularly when the surgery involves large amounts of electrocau-
tery. If a patient is pacemaker dependent, the device should be
reprogrammed to an asynchronous mode during surgery (VOO
or DOO), or a magnet should be placed over the device during
surgery. Implantable cardioverter defibrillator devices should
have their tachyarrhythmia treatment algorithms programmed
off before surgery and turned on after surgery to prevent
unwanted shocks due to spurious signals that the device might
interpret as ventricular tachycardia or fibrillation. If emergent
cardioversion is required, the paddles should be placed as far
from the implanted device as possible and in an orientation
likely to be perpendicular to the orientation of the device leads
(anterior-posterior paddle position is preferred). After the sur-
gery, the function of the implanted device should be assessed
and in some cases formally evaluated. In the case of an ICD, an
interrogated programmer printout should be produced to verify
that its antitachycardia function has been restored to its active
status.
Placement of a magnet over an implanted device has
variable effects depending on the type of device, its manu-
facturer, and its model. If a magnet will be used during
surgery in a patient with a pacemaker who is pacemaker
dependent, it should be applied before surgery to be certain
that appropriate asynchronous pacing is triggered by the
magnet. Magnet application will affect only the
antitachycardia function of an ICD. With some models of
ICDs, the magnet will first suspend the antitachycardia
(shocking) function and then actually turn the therapy off.
With other ICD models, the magnet will only temporarily
disable the shock function (while the magnet is in place), and
the therapy will then become active again on its removal (either
intentional or unintentional). Programming the shock function
off with an ICD programmer (and turning it back on after the
surgery) is the preferred method of addressing these issues.
Because some patients with ICDs are also pacemaker dependent,
the pacing function of the ICD may need to be programmed to
an asynchronous mode (eg, VOO or DOO) during surgery to
prevent electromagnetic interference–induced inhibition.
VII. Anesthetic Considerations and
Intraoperative Management
A. Intraoperative Management
There are many different approaches to the details of the
anesthetic care of the cardiac patient, including the use of
specific anesthetic agents or anesthetic techniques (eg, gen-
eral, regional, or monitored anesthesia care). Each has impli-
cations regarding anesthetic and intraoperative monitoring. In
addition, no study has clearly demonstrated a change in
outcome from the routine use of the following techniques: a
pulmonary artery catheter, ST-segment monitor, transesoph-
ageal echocardiography, or intravenous nitroglycerin. There-
fore, the choice of anesthetic technique and intraoperative
monitors is best left to the discretion of the anesthesia care
team. Intraoperative management may be influenced by the
perioperative plan, including the need for postoperative
monitoring, ventilation, analgesia, and the perioperative use
of anticoagulants or antiplatelet agents. Therefore, a discus-
sion of these issues before the planned surgery will allow for
a smooth transition through the perioperative period.
B. Perioperative Pain Management
From the cardiac perspective, pain management may be a
crucial aspect of perioperative care. Although no randomized
controlled study specifically addressing analgesic regimens
has demonstrated improvement in outcome, patient-
controlled analgesia techniques are associated with greater
patient satisfaction and lower pain scores. An effective
analgesic regimen must be included in the perioperative plan
and should be based on issues unique to a given patient
undergoing a specific procedure at a specific institution.
VIII. Perioperative Surveillance
A. Intraoperative and Postoperative Use of
Pulmonary Artery Catheters
Use of a pulmonary artery catheter may provide significant
information critical to the care of the cardiac patient; how-
ever, the potential risk of complications and the cost associ-
ated with catheter insertion and use must be considered.
Practice guidelines for pulmonary artery catheterization, as
well as methods of performing perioperative optimization of
the high-risk surgical patient, have been developed and
reported elsewhere (71,72). Evidence of benefit of pulmonary
artery catheter use from controlled trials is equivocal, and a
large-scale cohort study demonstrated potential harm (73).
B. Surveillance for Perioperative MI
Perioperative MI can be documented by assessing clinical
symptoms, serial ECGs, cardiac-specific biomarkers, compara-
tive ventriculographic studies before and after surgery, radioiso-
topic or magnetic resonance studies specific for myocardial
necrosis, and autopsy studies. Over the last decade, the diagnosis
of myocardial damage has become more sensitive with the
application of cardiac biomarkers. Measurement of troponin T or
I facilitates the recognition of myocardial damage with much
smaller amounts of injury. Because of the augmentation of
sensitivity, the threshold to diagnosis of an MI is lower and the
frequency greater (74). On the basis of current evidence, in
patients without documented CAD, surveillance should be re-
stricted to those patients who develop perioperative signs of
cardiovascular dysfunction. The diagnosis of a perioperative MI
has both short- and long-term prognostic value.
On the basis of the available literature, routine measurement
of troponin after surgery is more likely to identify patients
without acute MI than with MI. Moreover, studies of troponin
elevations neither consistently show associations with adverse
cardiovascular outcomes at any time point nor provide insight
into the effect of treatment on outcomes in patients with an
elevated troponin level. Although it is known that elevations in
troponin are more likely to occur in patients with more extensive
CAD, the role of revascularization in patients with an elevated
troponin level but no other manifestation of MI remains unclear.
Until each of these issues has been addressed, routine troponin
measurement cannot be recommended. Perioperative surveil-
lance for acute coronary syndromes with routine ECG and
cardiac serum biomarkers is unnecessary in clinically low-risk
patients undergoing low-risk operative procedures.
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IX. Postoperative and
Long-Term Management
Advances in preoperative risk assessment, surgical and anes-
thetic techniques, and better implementation of medical therapy
have served to decrease the frequency of cardiovascular com-
plications associated with noncardiac surgery. Despite these
advances, cardiovascular complications represent the most com-
mon and most treatable adverse consequences of noncardiac
surgery. Those patients who have a symptomatic MI after
surgery have a marked increase in the risk of death, reaching as
high as 40% to 70% (75). Because the consequences of infarc-
tion are so severe, management of patients must continue after
risk assessment to the postoperative setting.
A. Myocardial Infarction: Surveillance
and Treatment
In contrast to clinically silent elevations in troponin, the devel-
opment of coronary artery plaque rupture that results in throm-
botic coronary artery occlusion requires rapid intervention.
Although fibrinolytic therapy has been administered to patients
for life-threatening pulmonary embolus shortly after noncardiac
surgery, the fibrinolytic dosage has generally been less and has
been administered over a longer time interval than is standard for
the treatment of acute MI (76,77). Only a single small study (78)
has evaluated the role of immediate angiography and angio-
plasty among 48 patients who were believed able to take aspirin
and intravenous heparin and to undergo immediate angiography
and PCI; this study demonstrated that such a strategy is feasible
and may be beneficial. These reperfusion procedures should not
be performed routinely on an emergency basis in postoperative
patients in whom MI is not related to an acute coronary
occlusion. Moreover, because of the requirements for peripro-
cedural anticoagulation and postrevascularization antiplatelet
therapy, the benefits of revascularization must be weighed
against the risk of postoperative bleeding, individualizing the
decision for referral.
Therapy with aspirin, a beta blocker, and an angiotensin-
converting enzyme inhibitor, particularly for patients with
low ejection fractions or anterior infarctions, may be benefi-
cial, whether or not the patients are rapidly taken to the
catheterization laboratory (79). An extensive evidence-based
review of therapy for acute MI can be found in the ACC/AHA
Guidelines for the Management of Patients With Acute
Myocardial Infarction (79). Similarly, the ACC/AHA Guide-
lines for Unstable Angina/Non–ST-Segment Elevation Myo-
cardial Infarction represent an important template for man-
agement of this condition in the postoperative setting (5).
In the approach to the long-term postoperative management
of noncardiac surgery patients, one should first appreciate that
the occurrence of an intraoperative nonfatal MI carries a high
risk for future cardiac events that are often dominated by
cardiovascular death (80,81). Patients who sustain a periopera-
tive MI should have evaluation of LV function performed before
hospital discharge, and standard postinfarction therapeutic med-
ical therapy should be prescribed as defined in the ACC/AHA
acute MI guidelines (3). The ACC/AHA guidelines for post-MI
evaluation in these types of patients should be followed as soon
as possible after surgical recovery.
B. Long-Term Management
Although the occasion of noncardiac surgery brings a period of
increased cardiovascular risk, physicians should also use the
opportunity to ensure appropriate cardiovascular medical ther-
apy. In the recently released ACC/AHA 2005 Guidelines for the
Management of Patients With Peripheral Arterial Disease (82),
treatment with a statin to achieve a low-density lipoprotein level
of less than 100 mg/dL, control of blood pressure to less than
140/90 mm Hg, cigarette smoking cessation, and antiplatelet
therapy all received Class I indications (82).
It is important that the care team responsible for the
long-term care of the patient be provided with complete
information about any cardiovascular abnormalities or risk
factors for CAD identified during the perioperative period.
X. Conclusions
Successful perioperative evaluation and management of high-
risk cardiac patients undergoing noncardiac surgery requires
careful teamwork and communication between surgeon, anes-
thesiologist, the patient’s primary caregiver, and the consultant.
In general, indications for further cardiac testing and treatments
are the same as in the nonoperative setting, but their timing is
dependent on several factors, including the urgency of noncar-
diac surgery, patient-specific risk factors, and surgery-specific
considerations. The use of both noninvasive and invasive pre-
operative testing should be limited to those circumstances in
which the results of such tests will clearly affect patient man-
agement. Finally, for many patients, noncardiac surgery repre-
sents their first opportunity to receive an appropriate assessment
of both short- and long-term cardiac risk. Thus, the consultant
best serves the patient by making recommendations aimed at
lowering the immediate perioperative cardiac risk, as well as
assessing the need for subsequent postoperative risk stratifica-
tion and interventions directed at modifying coronary risk
factors. Future research should be directed at determining the
value of routine prophylactic medical therapy versus more
extensive diagnostic testing and interventions.
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